Merck has shocked ALK-Abello by returning the rights to three sublingual allergy immunotherapy tablets, triggered an 18% drop in the Danish firm's share…

We can rebuild him; we have the technology--but Americans question if we should in a new survey designed to assess attitudes to modern biotechnology advances.

Kite Pharma has always been focused on engineering a patient’s own T cells to treat their cancer. But now, it’s in-licensed tech to create off-the-shelf T-cell…

Tokai had hoped that its prostate cancer candidate could best Medivation’s Xtandi, but now the microcap biotech has instead discontinued that Phase III pivotal…

AstraZeneca and partner Moderna Therapeutics are heading to the lab for the first time together with their experimental cardiometabolic drug AZD8601.

The FDA has granted breakthrough therapy status to J&J and Genmab's Darzalex as a second-line treatment for multiple myeloma, positioning it for a…

Newron Pharmaceuticals has seen a much-needed quick turnaround for its lead Parkinson’s drug as it can now resubmit its candidate in the U.S.--just four months…

Seattle startup Just Biotherapeutics has nabbed another $14 million to work on affordable biologics with a team lifted from Amgen as well as major backing…